Medicine
Survanta 25 mg/mL inhalation suspension
Survanta 25 mg/mL inhalation suspension is a prescription medicine containing Beractant for endotracheal use, marketed by AbbVie, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store unopened vials refrigerated at 36°F to 46°F (2°C to 8°C). Do not shake…
Key facts
- Active ingredient (INN)
- Beractant
- Brand
- Survanta
- Strength
- 25 mg/mL
- Dosage form
- Inhalation suspension
- Route
- Endotracheal
- Packs
- 1 vial
- Marketing authorisation holder
- AbbVie
- Manufacturer
- AbbVie
- Origin register
- US FDA, United States
- Storage
- Store unopened vials refrigerated at 36°F to 46°F (2°C to 8°C). Do not shake. Protect from light. Store vials in carton until ready for use.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 July 1991
- Identifiers
- RxCUI 259034, 861715DailyMed set ID 7ef9e3a5-fc39-4ae1-0dad-6b47a1684635NDC 0074-1040Application BLA020032
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 1 July 1991 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Beractant is a surfactant indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. It is available as inhalation suspension for endotracheal use. MedsAcross supplies Beractant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BeractantFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Survanta prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
Need Survanta 25 mg/mL inhalation suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.